Buy This Pharma Stock at a Discount

This is one of the best oversold pharma stocks to buy now ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here. Prefer to view this content on our website? Click here. Dear Fellow Investor, Company: AbbVie (SYM: ABBV) One of the most oversold pharmaceutical stocks to buy for the long haul is AbbVie (SYM: ABBV). With a yield of 3.74%, AbbVie discovers, develops, manufactures, and sells pharmaceuticals worldwide. It offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Trading Whisperer This Stock Is A High Roller’s Dream Imagine a company so efficient it turns $1 into $2.13 in revenue, with a 20% retention rate nearly double the industry average. That’s the story behind this iGaming powerhouse. While others chase sports bettors, this company is focused on high-margin VIP casino players—the whales who demand the best and aren’t afraid to pay for it. Learn why smart investors are paying attention. Most recently, the company reported topline results from its Phase 3 study of tavapadon for the treatment of early Parkinson’s disease.  Not only did the treatment meet its primary endpoint of showing statistically significant improvement from baseline compared to placebo in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale, but it also met its secondary endpoint showing statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living in the tavapadon group compared to placebo, as noted in a recent AbbVie press release. Even better, the company just increased its dividend to $1.64 from $1.55 per share, payable on February 14, 2025 to shareholders of record as of January 15, 2025. Since 2013, ABBV’s dividend has now been increased by about 310%.  Plus, analysts at Piper Sandler just raised their price target on ABBV to $220 from $212 with an overweight rating. We also have to consider that ABBV is cheap, trading with a price to earnings growth (PEG) ratio of just 0.41x, which is down from 3.21x year over year. American Stock Investor Elon Musk Predicts Artificial Intelligence Doomsday There is a massive bottleneck for one critical AI component. And there’s just one company in America that can fix it. Early investors could see as much as 528% profit when this company’s share price surges. Get the full story right here. Earnings Haven’t Been Too Shabby Either In its most recent quarter, AbbVie’s EPS of $3 beat by eight cents. Revenue of $14.46 billion, up 3.83% year over year, beat by $183.12 million. Skyrizi and Rinvoq revenues were up 50.8% year over year to $3.2 billion and 45.3% to $1.6 billion, respectively, during the quarter, with its immunology portfolio generating over $7 billion, up 3.9% year over year. Meanwhile, the company’s arthritis treatment Humira dropped about 37.2% to $2.2 billion thanks to U.S. generic competition. "We delivered another quarter of strong commercial execution and significant pipeline progress," said Robert A. Michael, CEO, AbbVie, as quoted in the company’s earnings release. Huge Alerts With gold achieving record breaking highs in 2024, this is the #1 gold stock to watch in 2025! Gold’s allure is spreading as the metal locks in fresh records. This stock looks like a hidden opportunity as renowned gold investor Eric Sprott has gone BULLISH on the company! Given gold’s bullish performance in 2023 and in 2024, many investors have turned to the metal to stabilize their portfolios and mitigate the devastating effects of inflation and global turmoil. The yellow metal has long been considered a safe haven. Gold has had a record-breaking climb in 2024, and many analysts predict more gains next year. Get the ticker details here... Do you currently own any shares of pharma stocks undergoing promising drug trials? Are there any other pharma stocks you have your eye on right now? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of High Roller Technologies Inc. (NYSEAMERICAN:ROLR). The compensation consists of up to $4,000 was received/will be received from Market Jar Media. This compensation should not be considered as an endorsement of the securities of adviser High Roller Technologies Inc. (NYSEAMERICAN:ROLR) and we are not responsible for any errors or omissions in any information provided about the securities of High Roller Technologies Inc. (NYSEAMERICAN:ROLR) by Trading Whisperer or Market Jar Media. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 1/14/2025. We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of US Gold Corp. (NASDAQ: USAU). The compensation consists of $2,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of adviser US Gold Corp. (NASDAQ: USAU) and we are not responsible for any errors or omissions in any information provided about the securities of US Gold Corp. (NASDAQ: USAU). We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 01/14/2025. Behind the Markets Unsubscribe invisiblelink